Abstract
Tendering has proven its efficacy mainly in generic procurement, however due to several impediments, its penetration among European Countries is low and data regarding its long-term effect are scarce. MethodsWe assess the long-term effect of tendering on prices of branded products in Cyprus through the utilization of a repeated measures generalized linear model. We used products that were continuously included in Cyprus formulary for seven consecutive years. ResultsTendering demonstrates a statistically significant reduction, superior to reduction reached with official external price referencing scheme, and it retains its long-term potency on price reduction. It is mediated by other variables such as interchangeability, in-patient status and indication of the product. Volume of sales is not related to the rate of reduction. ConclusionsTendering can be considered as a potent pricing and reimbursement method in the long-term. It is a context sensitive scheme, therefore it must be applied with regards to each country׳s operational health policy framework.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
